SEC Form 4 · accession 0001209191-18-049421
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Gonyer
Officer — President and CEO · Director
Period of report
Aug 31, 2018
Accepted (ET)
Sep 5, 2018 · 10:17 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2018 | J | 6,901 | $1.63 | A | 319,544 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were purchased under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c).